XOMA Royalty Valuation Multiples

XOMA Royalty Overview

About XOMA Royalty

XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.

Founded

1981

HQ

Employees

13

Website

xoma.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $56M

EBITDA: $21M

EV

$486M

Valuation Multiples

Multiples.vc

Start free trial

XOMA Royalty Financials

XOMA Royalty reported last 12-month revenue of $56M and EBITDA of $21M.

In the same LTM period, XOMA Royalty generated $56M in gross profit, $21M in EBITDA, and $24M in net income.

XOMA Royalty P&L

In the most recent fiscal year, XOMA Royalty reported revenue of $52M and EBITDA of $48M.

XOMA Royalty expects next 12-month revenue of XXX and NTM EBITDA of XXX

XOMA Royalty Stock Performance

XOMA Royalty has current market cap of $438M, and enterprise value of $486M.

XOMA Royalty's stock price is $36.72.

XOMA Royalty Valuation Multiples

XOMA Royalty trades at 8.7x EV/Revenue multiple, and 23.5x EV/EBITDA.

XOMA Royalty Financial Valuation Multiples

As of April 11, 2026, XOMA Royalty has market cap of $438M and EV of $486M.

Equity research analysts estimate XOMA Royalty's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

XOMA Royalty has a P/E ratio of 17.9x.

XOMA Royalty Margins & Growth Rates

XOMA Royalty's revenue in the last 12 month grew by 16%.

XOMA Royalty's revenue per employee in the last FY averaged $4.0M, while opex per employee averaged $0.0M for the same period.

XOMA Royalty's rule of 40 is 512% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

XOMA Royalty's rule of X is 1214% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

XOMA Royalty Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

XOMA Royalty M&A Activity

XOMA Royalty acquired XXX companies to date.

Last acquisition by XOMA Royalty was on XXXXXXXX, XXXXX. XOMA Royalty acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

XOMA Royalty Investment Activity

XOMA Royalty invested in XXX companies to date.

XOMA Royalty made its latest investment on XXXXXXXX, XXXXX. XOMA Royalty invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).